

INDEX

Volume Four January through December 1970

DRUG INTELLIGENCE AND CLINICAL PHARMACY

January	Pages	1 - 28	July	Pages	169 - 200
February	Pages	29 - 56	August	Pages	201 - 228
March	Pages	57 - 84	September	Pages	229 - 264
April	Pages	85 - 112	October	Pages	265 - 296
May	Pages	113 - 140	November	Pages	297 - 328
June	Pages	141 - 168	December	Pages	329 - 360

A

Acetaminophen, interactions, 146
Acetazolamide, and renal stone formation, 199
Acetylcholine, 60
Actinomycin-D, folliculitis after administration, 54
Adrenergics, drug interactions, 174
Adults, biological half-lives of drugs, 332
Adverse drug reactions, monitoring, 101
Adverse drug reactions, 45, 64, 90, 149, 221, 233, 307
Age, effect on biological half-life, 332
Albright's irrigating solution, formulation, 99
Aldactone, excretion data, 190
Allopurinol, toxicity, 90, 262
4-Allyloxy-3-chlorophenylacetic acid, analgesic activity, 291
Alprenolol, cardiovascular effects, 138
Amantadine
 in influenza, 24
 in parkinsonism, 260, 292
Ambenonium, interactions, 60
Amino acid solutions, in postoperative patients, 215
Aminorex-C¹⁴, excretion data, 232
Amobarbital, interactions, 146
Amphetamine
 excretion data, 232
 in anxiety states, 253
 intoxication, 295
 metabolism, 351
Amphotericin B, clinical use, 165
Ampicillin
 dosage, 45
 excretion data, 190
 in granuloma inguinale, 52
 stability, 204
Ampuls, glass contamination, 185
Anabolic steroids, interactions, 146
Analexin, see Phenylramidol
Analgesics, and renal abuse, 262
Anemia, aplastic, drug-induced, 262
Angiotensinamide, stability, 72
Antabuse, see Disulfiram
Anti-arrhythmic agents, 294
Antibiotics
 increased activity, 292, 293
 in gonococcus, 111
 ointment, 164
 potassium and sodium content, 13
 stability, 99
 systemic prophylaxis, 53
Anticancer agents, metabolism, 351
Anticholinergics, 88
Anticoagulants
 adrenal hemorrhage with, 295
 and breast feeding, 199
 interactions, 10, 146, 251, 300
Antihypertensive agents, 187
Antisubstitution laws (edit.), repeal, 115
Aptin, see Alprenolol
AristoSpan, see Hexacetonide ester triamcinolone
Arsenic, in detergents, 166
Ascorbic acid
 effect of iron salts on stability, 16
 stability of injection, 43
Aspirin
 adverse reaction, 307
 excretion data, 190, 232
 in disorders of intrinsic clotting, 54
 self-poisoning, 328
Atromid-S, see Clofibrate

Atropine
 interactions, 88
 toxicity from eyedrops, 226
Audit of pharmacy service, 157
Automatic data processing, in drug monitoring, 101
Azathioprine
 in pemphigus vulgaris, 352
 teratogenic effect, 149
 with prednisone in renal disease, 225
Azulfidine, see Salicylazosulapyridine

B

Ba-30803, new anti-anxiety agent, 226
Bacitracin, adverse reaction, 64
Balanced salt solution, sterile, formulation, 99
Ben-Hur, N. (co-author), Fluorouracil Treatment of Multicentric Basal Cell Carcinoma and Actinic Hyperkeratosis, 181
Benya, Theodore J. (author), Drug Order Control system ("D.O.C."), 283
Benzocyclan, new anti-serotonin, 68
Benzocetamine, see Ba-30803
Benzphetamine, excretion data, 232
Benztropine, adverse reaction, 129, 253
Benzyl alcohol, and polysorbate 80, 156
Berman, Alex (author), book review, 278
Bethanidine, comparison with α -methyl dopa and reserpine, 327
Bibliography
 biopharmaceutics, 17
 drug interactions, 174, 217
Biologicals, new, 116
Biological half-life, see Half-life, biological
Biopharmaceutics, 7, 17, 32, 77, 92, 132, 160, 232, 332
Blood forming and coagulation, interactions, 251
Blood pressure, drugs to control, 187
Book Reviews
 American Drug Index 1970, 124
 Biochemistry of Alkaloids, 224
 Control of Chemotherapy, 124
 Food and Drug Legislation in the New Deal, 278
 Pharmaceutical Technology - Fundamental Pharmaceutics, 224
 Pharmacological Facts and Figures, 124
 Pharmacology Applied to Patient Care, 278
 Recent Advances in Pharmacology, 278
 Specifications for the Identity of Food Additives. Some Antibiotics, 27
 Techniques of Medication, 124
 WHO Expert Committee on Drug Dependence, 27
Borgsdorf, Lawrence R. (co-author), Drug Information Analysis Service - The DIAS Rounds, 307
Brodie, Donald C. (author), Drug Utilization - A Public Health Problem (edit.), 203
Butazolidin, see Pyrazole compounds

C

Cacace, Larry (co-author), Treatment of Hypertensive Emergencies with Sodium Nitroprusside, 187
Cain, Rosalyn M. (author), Physician-Pharmacist Interface in the Clinical Practice of Pharmacy, The, 38
Calcium, infusions in osteoporosis, 52
Capsules, dissolution rate, 132
Carbachol, stability of solutions, 72
Carbenicillin, stability, 204
Carbochromen, in coronary insufficiency, 292

Carcinoma, basal cell, 181
Cardiac drugs, interactions, 272
Cardiovascular drugs, interactions, 272, 276
Carisoprodol, drug interactions, 217
Case studies, medical, 322
Catheters, bacterial contamination, 100
Cephalexin
 clinical studies, 52
 properties, 139
Cephaloglycin (Lilly - Japan), 116
Chemical and biological weapons, 294
Children, biological half-lives of drugs, 332
Chloral hydrate, interactions, 146
Chloramphenicol
 encephalopathy, 295
 interactions, 146
 succinate sodium, irrigating solution, 10
Chlormezanone, drug interactions, 217
Chloromycetin, see Chloramphenicol
Chlorpromazine
 adverse reactions, 129
 assay, 294
 in hiccups, 253
Chlorpropamide, half-life, 291
Chlorzoxazone, drug interactions, 217
Cholestyramine, adverse reaction, 26, 221
Cholinesterase inhibitors, 60
Chorbajian, Torcom (co-author), Digital Analog Simulation of Pharmacokinetic Models: I. MIDAS, 315
Clean rooms, 314
Clindamycin (Upjohn - England), 116
Clinical pharmacy, 10, 38, 64, 73, 90, 129, 149, 209, 221, 253, 300, 307, 322
Clinical trials, 53
Clofibrate
 interactions, 146, 276
 teratogenic effects, 129
Colistimethate, adverse reaction, 129
Collective bargaining, and hospital pharmacists, 59
Community pharmacies, role in education, 271
Computer applications, in hospital pharmacy, 240
Computers, analog, 315
Computers, digital, 315
Computers, drug effect prediction by, 291
Conray, adverse reaction, 45
Contamination control, 313
Contamination, in a clean room, 155
Continuing education, 322
Corticosteroids
 adverse reaction, 307
 topical, 260
Cosmetics, 49
Coull, James (co-author), Digital Analog Simulation of Pharmacokinetic Models: I. MIDAS, 315
Coumarin, enteral and percutaneous absorption, 111
Coumermycin-A₁, antibacterial activity, 165
Cromolyn (Intal - Fison, England), 116
Cuttler, Milton (co-author), USP Standards in Military Drug Purchasing, 257
Cyanoacrylate, hemostasis action, 67
Cyclophosphamide, adverse reaction, 307
Cycloserine, stability, 72
Cytarabine (Cytostar - Upjohn), 116
Cytostar, see Cytarabine

D

Danckwerts' model, 77

Dapson, agranulocytosis reaction, 228
 Defense Personnel Support Center, 257
 de Haen, Paul (author), New Products Parade 1969, Annual Parade of New Drugs, 116
 Derewicz, Henry J. (author), Approach to Pharmacy Programs Development, An, 157
 Desacetoxycephaloglycin, see Cephalixin
 Dextran 40, in thromboembolism, 24
 Dextroamphetamine, poisoning, 149
 Dextrose solution, stability, 16
 Dextrothyroxine, interactions, 276
 DIAS Rounds, 10, 45, 64, 90, 129, 149, 221, 253, 307
 Diazepam
 addition to, 354
 interaction with Mandrax, 261
 interaction with muscle relaxants, 261
 intravenous, in dentistry, 353
 Diethyl thiourea, reaction, 228
 Digitalis glycosides, interactions, 272
 Digitoxin
 absorption, 10
 metabolism, 350
 Digoxin
 absorption, 10
 assay, 53
 concentration, 350
 Dilantin, see Diphenylhydantoin
 Diphenylhydantoin
 exanthem from administration, 228
 interactions, 146
 intolerance induced by isoniazid, 328
 intoxication following halothane, 264
 Disease, effect on biological half-life, 332
 Disintegration test, tablets, 92
 Dipotassium chlorazepate, pharmacology, 293
 Disodium cromoglycate, in asthmatics, 111
 Dissolution rate, 17, 32, 77, 92, 132, 160, 190, 232
 Distefano, Rose Marie (co-author), Clinical Radiopharmacy, 209
 Disulfiram, interaction, 10, 146
 Diuretics, ototoxicity, 261
 Dopar, see Levodopa
 Doriden, see Glutethimide
 Dosage, effect on biological half-life, 332
 Dosage forms, 116, 190, 232
 Doxepin (Sinequan - Pfizer), 116
 Dressings, bacterial contamination, 44
 Drug absorption, 7, 32
 Drug Actions, Interactions and Reactions, 24, 52, 67, 111, 138, 164, 198, 225, 260
 Drugs, and clinical trials, 53
 Drug antagonism, 60, 88, 146
 Drug biotransformation interactions, 296
 Drug combinations, 116
 Drug compendia, 116, 168
 Drug control, 257, 283
 Drug dosage, calculations, 315
 Drug efficacy, monitoring, 101
 Drug efficacy study, 116
 Drug formulation, phosphates for oral use, 4
 Drug information, 10, 45, 64, 90, 101, 129, 149, 221, 240, 253, 307
 Drug information sources, 45
 Drug Interactions
 editorial, 173
 monitoring, 101
 pharmacokinetics, 54
 reports, 10, 45, 60, 64, 88, 90, 116, 146, 174, 217, 240, 251, 272, 296, 300, 348
 Drug labeling, 283
 Drug metabolism, in man, 296, 348
 Drug monitoring, 101
 Drug potentiation, 146
 Drug profiles, 73, 283
 Drug stability, 204
 Drug surveillance, 352
 Drug synergism, 60, 88
 Drug synthesis, 116
 Drugs, biological half-lives in infants, 332
 Drugs, effects on bilirubin metabolism, 350
 Drugs (generic and proprietary names), 116
 Drugs, investigational, 116
 Drugs, new, 116
 Drug therapy, pharmacist's role, 38
 Dyskinesias, drug-induced, 226

E

Echthiophate iodide, interactions, 60

Editorials

ASHP Convention Decisions, 146
 Can Professional Time Be Better Used?, 299
 Drug Intelligence and Clinical Pharmacy—A Nonprofit Publication, 351
 Drug Utilization—A Public Health Problem, 203
 Economic Benefits and a Professional Society, 59
 IPA in the 70's, 87
 New Directions for the Pharmacopeia, 3
 Pharmacy's New Emphasis, 231
 Repeal of Antisubstitution Laws, 115
 Research in Community Practice, 271
 Significance and Interpretation of Drug Interaction Information, 173
 The Secret Vote in Representative Assemblies, 31
 Edrophonium, interactions, 60
 Education
 community pharmacies in, 271
 continuing, 322
 in radiopharmacy, 209
 Effective dose (ED₅₀), 49
 Enzyme induction in man, 351
 Ephedrine, drug interactions, 174
 Epidemiological methods, in drug monitoring, 101
 Epinephrine
 adverse reactions, 228
 and norepinephrine, interactions, 174
 interactions, 174
 Equipment, in radiopharmacy, 209
 ER 115, see Temazepam
 Ergot, poisoning, 328
 Erythrocytes, stability, 72
 Erythromycin, excretion data, 232
 Ethacrynic acid
 effect on intracranial pressure, 112
 ototoxicity, 26
 Ethambutol, adverse reaction, 221
 Ethchlorvynol, interactions, 146
 Ether, for hiccups, 260
 Ethylene oxide
 residual in plastics, 100
 sterilization, 214, 313
 Etryptamine, excretion data, 232
 European Hospital Pharmacy Study Mission, 55, 140
 Europe, new drugs 1969, 116

F

Factor IX Complex, Human (Konyne - Cutter), 116
 Feinberg, Max (co-author), USP Standards in Military Drug Purchasing, 257
 Filter
 disposable pleated membrane, 311
 holder, 311
 in-line, 128
 Swinny adapter, 69
 Fleet's Phospho-Soda, treatment of hypercalcemia, 4
 Flufenamic acid (Parke Davis - Japan), 116
 5-Fluorouracil, 181
 Fluphenazine decanoate (Squibb - Germany), 116
 Fluprednisolone, in diabetics, 292
 Folic acid, interactions, 64
 Formulary system, 157
 Francke, Don E. (author)
 book review, 124
 editorials, 3, 31, 59, 115, 145, 231, 271, 331
 Frazier, Walter M. (author), Can Professional Time Be Better Used? (edit.), 299
 Furosemide
 adverse reaction, 295, 307, 354
 in renal disease, 225

G

Gantrisin, see Sulfisoxazole
 Gas aerator, 153
 Gastrointestinal absorption, 7
 Germicides, phenolic, depigmentation from, 328
 Gill, Alfred W. (co-author), Prediction of Pharmaceutical Stability of Parenteral Solutions II, 243
 Glasser, Arthur C., new dean at Cincinnati, 55
 Glutethimide, interactions, 146
 Glyburide HB 419 (Hoechst and Boehringer-Mannheim, Germany), 116
 Glycerol formal, solvent for isoniazid detoxification, 139
 Glycerol guaiacolate, adverse reaction, 166

Goeman, Judith A. (co-author), Prediction of Stability of Parenteral Solutions, 69

Griseofulvin

adverse reaction, 45
 excretion data, 190, 232
 interactions, 146

Guanethidine, ophthalmic solution, 353

Guanidinium antihypertensives, metabolism, 349

H

Haldol, see Haloperidol

Half-life, biological, 332

Halidor, see Benzocyclan

Halothane, effect on BSP clearance, 261

Haloperidol, interactions, 146

Hartshorn, Edward A. (author)

Drug Interactions. Autonomic Drugs: Parasympatholytic Agents, 88; Parasympathomimetic Agents, 60; Skeletal Muscle Relaxants, 217; Sympathomimetic Agents, 174; Blood-Forming and Coagulation Agents, 251; Cardiac Drugs, 272; Anti-hyperlipemic Agents, 276
 Significance and Interpretation of Drug Interaction Information (edit.), 173

Harvey A. K. Whitney Award, 1970, 83

HEPA (High Efficiency Particulate Air) filters, 155

Heparin

interactions, 251

intestinal absorption, 53

I.V. in elderly women, 328

kinetics, 348

therapeutic use, 129

Heparin-heparinoid, side effects, 68

Hernandez, Luis (co-author), Clinical Radiopharmacy, 209

Hexacetonide ester triamcinolone (Aristospan-Lederle), 116

Hiccups, ether in treatment, 260

Hirschman, Joseph L. (co-author), Drug Information Analysis Service - The DIAS Rounds, 10, 45, 64, 90, 129, 149, 221, 253, 307

History, dissolution rate, 32

Ho, Norman F. H. (co-author)

Prediction of Stability of Parenteral Solutions I, 69; II, 243

Hospitals, role in drug monitoring, 101

Hutchinson, Richard Allen (author), Journal Club—A Method of Inservice Clinical Education for Pharmacists, 322

Hydrocortisone, side effects, 167

Hyoscine, intramuscular, for motion sickness, 352

Hypercalcemia, 4

Hypertension, malignant, 187

I

Iatrogenic disease, 307

Imipramine, adverse reaction, 129, 221, 253

Imuran, see Azathioprine

Incompatibilities, injections, 215

Indocin, see Indomethacin

Indomethacin, interactions, 146

Infants, biological half-lives of drugs, 332

Inhalation equipment

disinfection, 16

source of contamination in, 156

Inhalation therapy

infections from medications, 295

metabolism of anesthetics, 349

Injections

preparation without autoclaving, 156

stability of formulations, 156

Inpatient pharmacy service, 283

Insulin

adsorption to bottles and tubing, 314

interactions, 10

Intal, see Cromolyn

International Pharmaceutical Abstracts (edit.), 87

International Pharmaceutical Federation, meeting, 140

Intraperitoneal infusion, in children, 16

Intravenous solutions

additive programs and industry, 314; booklet, 154

feedings, long-term, 314

infusion pumps, 153

particulate contamination analysis, 280

stability, 204

Investigational drugs, 116

In vivo-in vitro correlations, 160, 190, 232

Iodide, induction of myxedema, 54

Iron
-dextran in rheumatoid arthritis, 264
interactions, 251
Irrigating solution, Albright's, 99
Isoniazid, adverse reaction, 221
Isoproterenol
interactions, 174
sustained action tablets, 45, 149
Isosorbide, in angina, 25
I.V. Additive Review, 13, 41, 69, 97, 125,
153, 183, 213, 243, 279, 311

J

Jacobs, John (co-author), Ampicillin and Carbenicillin Stability in Commonly Used Infusion Solutions, 204

K

Kanamycin
dosage, 45
ototoxicity, 262
Keratitis, 181
Konyne, see Factor IX Complex, Human
Kramer, Warren (author), Inspection for Particulate Matter Essential to I.V. Additive Program, 311
Ku, Lauren L. J. H. (co-author), A Clinical Study of Drug Interaction and Anticoagulant Therapy, 300

L

Laboratory apparatus, tablet testing, 92
Lactulose, in encephalopathy, 25
Laminar air flow units, 155, 213, 249
Larodopa, see Levodopa
Laser-induced cataract, 261
Lasix, see Furosemide
Levodihydroxyphenylalanine, see Levodopa
Levodopa
adverse reactions, 294, 295
approved by FDA, 200
in seborrhea of parkinsonism, 353
in senile dementia, 198
Lidocaine, in ventricular arrhythmias, 199
Lien, Eric J. (author), Physicochemical Properties and Gastrointestinal Absorption of Drugs, 7
Lignocaine, oral, 198
Lincromycin, adverse reactions, 295
Lipids, effects of drugs on metabolism, 351
Literature, 27, 124, 224, 278, 322
Lithium carbonate (England, Germany), 116
Lithium carbonate, in mania, 198
Local anesthetics, antimicrobial activity, 293
Lowenthal, Werner (author), Therapeutic Incompatibilities: Storage and Retrieval by Computer, 240

M

Mafenide cream (Sulfamylon cream - Winthrop), 116
Magnesium
oral salts, 64
physiology and pharmacology, 353
Marihuana
adverse reactions, 25, 262
use among urban adults, 67
Massachusetts General Hospital, I.V. policies, 125
Matulane, see Procarbazine
Maudlin, Robert K. (co-author), Drug Information Analysis Service—The DIAS Rounds, 10, 45, 64, 90, 129, 149, 221, 253
Medazepam (Roche - Germany), 116
Median lethal dose (LD₅₀), 49
Medication orders, 283
Membrane permeability, in hemodialysis, 185
Mephensin, drug interactions, 217
Mephentermine, metaraminol, drug interactions, 174
Merobamate, interactions, 146
Mercury, self-poisoning, 68
Meruvax, see Rubella Virus Vaccine
Metaxalone, drug interactions, 217
Methicillin, adverse reaction, 221
Methocarbamol, drug interactions, 217
Methotrexate
adverse reaction, 307
interactions, 64, 226, 262
Methotrimoprazine, agranulocytosis with, 295

Methoxyflurane, interaction with tetracycline, 166
Methylodopa, adverse reaction, 90, 129
 α -Methylodopa, comparison with bethanidine and reserpine, 327
Methylphenidate
in anxiety states, 253
interactions, 146
Methylprednisolone, excretion data, 190
Methylthiouracil, interactions, 146
Methysergide, in mania, 327
Microbiological testing, non-sterile preparations, 249
Microbiology
hygienic factors, 282
raw material requirements, 282
MIDAS (Modified Integration Digital Analog Simulator), 315
Millipore technology, 279
Mithramycin, in Paget's disease, 327
Models, pharmacokinetic, 315
Monosodium glutamate, adverse reaction, 354
Morphine
adverse reaction, 45
stabilization of solutions, 99
Multiple dose containers, contamination, 314

N

Nalidixic acid, hemolysis after administration, 199
Nalorphine, in morphine dependency, 68
 β -Naphthol derivatives, as preservatives, 16
Narcotic addicts, I.V. use, 155
Narcotic analgesics, 293
Nathan, Ivor (co-author), Ampicillin and Carbenicillin Stability in Commonly Used Infusion Solutions, 204
National Formulary, standards, 257
Neomycin
adverse reaction, 64
interactions, 146
toxicity, 26
Neostigmine
interactions, 60
warning in use for megacolon, 112
Neuman, Z. (co-author), Fluorouracil Treatment of Multicentric Basal Cell Carcinoma and Actinic Hyperkeratosis, 181
Neutra-Phos, treatment of hypercalcemia, 4
New drug applications (NDA), 116
News, 55, 83, 140, 168, 200, 228
Nilevar, see Anabolic steroids
Nitrofurantoin
in urinary tract infections, 52
pleuropneumonic reactions, 54
Nitrogen dioxide, toxicity, 264
Norepinephrine, drug interactions, 174
Norethandrolone, see Anabolic steroids
Noyes-Whitney Law, equation, 77
Nuclear medicine, 209
Nylidrin, drug interactions, 174
Nystatin
allergic contact dermatitis from, 328
in monilial infections, 221

O

Oddis, Joseph A., receives Whitney Lecture Award, 83
Oral contraceptives, adverse reaction, 112, 146
Organophosphate cholinesterase inhibitors, interactions, 60
Orphenadrine, interactions, 88
Orinase, see Tolbutamide
Oxazepam, adverse reactions, 129, 149
Oxymethobanol, pharmacology, 292
Oxyphenbutazone, see Pyrazole compounds
Oxyquinoline, adverse reaction, 354
Oxytetracycline, azotemia reaction, 68, 166

P

Papaverine, hepatotoxicity, 112
Parasympathomimetic agents (cholinergics), 60
Parathyroid hormone, metabolism, 351
Parenteral nutrition, long-term, in infants, 25
Parenteral solutions, see I.V. Additive Reviews
Particulate contamination, 33, 44, 100, 311
Peel-seal pouch for sterile products, 311
Penicillamine, metabolism, 351
Penicillin
allergy, 295
inactivation by carbohydrate solutions, 280

Penicillin V, excretion data, 232
Pentazocine
addiction, 261
metabolism, 349
tolerance and toxicity, 26
Pentazocine (Talwin - Winthrop), 116
Peritoneal dialysis, 100
Perphenazine, adverse reaction, 253
Pharmacokinetics, 7, 54, 77, 132, 160, 296, 315, 332; see also Biopharmaceutics
Pharmacy and therapeutics committee, 157
Pharmacy schools, government grant, 228
Phenobarbital, interactions, 146
Phenothiazines, adverse reaction, 64, 221, 253
Phenylbutazone, see Pyrazole compounds
Phenylephrine, interactions, 174
Phenylpropanolamine
effect on phenolamine test, 25
interactions, 174
Phenylamidol, interactions, 146
Phosphate solution, for hypercalcemia, 4, 14
Physician-pharmacist interface, 38
Physicians' orders, 283
Physostigmine, interactions, 60
Pilocarpine, interactions, 60
Pilocarpine nitrate, therapeutic use, 129
Piperacetazine (Quide - Dow Chemical), 116
Placidyl, see Ethchlorvynol
Poison control, 149
Policies and procedures
I.V. additive program, 183, 213, 279
pharmacy and therapeutics committee, 157
Pollution, environmental, 24
Polymyxin, adverse reaction, 129
Prednisolone, new anti-inflammatory, 260
Prednisone
adverse reactions, 149, 221
after renal transplant, 292
excretion data, 190
with azathioprine in renal disease, 225
Preservatives
inactivation, 16
pharmaceutical, 250
Proadifen, anti-arrhythmic effects, 293
Probenecid, relation to penicillin levels, 199
Procainamide
interactions, 22
pharmacokinetics, 350
Procarbazine hydrochloride (Matulane - Roche), 116
Programming, computer, 315
Propellants, for corticoid aerosol, 138
Propoxyphene, review, 327
Propranolol
in angina, 24, 25
interactions, 272
Protamine zinc insulin diluent, formulation, 97
Protein binding, effect on biological half-life, 332
Prothrombin time, drug effects, 300
Psychoactive drugs, hazards of prescribing, 295
Psychotropic agents, 294
Pyrazole compounds, interactions, 146
Pyrogens, preparation, 313

Q

Quality control, 282, 313
Quide, see Piperacetazine
Quinacrine, action, 293
Quinidine, interactions, 146, 272
Quinine
adulterant in heroin, 264
interactions, 146

R

Radioisotopes
disposable containers, 72
handling, 209
Radiopharmacy, 209
Radiopharmaceuticals, injectable, 186
Ravin, Robert L. (author), Steps in Starting an I.V. Additive Program, 13, 41, 97
Research, drug, 116
Reserpine
bronchospasm after administration, 54
comparison with bethanidine and α -methyl-dopa, 327
Residency programs, 168
Respiratory disease units, source of infections in, 156

Rifampicin
adverse reaction, 354
stability, 15

Rimantadine, in influenza, 24

Ritalin, see Methylphenidate

Ritschel, W. A. (author)
book reviews, 224, 278
Biological Half-Life, 332

Rubber closures, effect on benzyl alcohol, 44

Rubella Virus Vaccine (Philips Roxane; Rubelogen - Parke Davis), 116

Rubelogen, see Rubella Virus Vaccine

S

Sacks, Theodore (co-author), Ampicillin and Carbenicillin Stability in Commonly Used Infusion Solutions, 204

Salicylamide, excretion data, 190, 232

Salicylates
adverse reactions, 146, 307
interactions, 146
metabolism, 349

Salicylazosulfapyridine, pancreatitis reaction, 227

Salter, Fred J. (author), Inorganic Phosphates in the Treatment of Hypercalcemia, 4

Salvicyclin, new antibacterial-antimycotic, 139

Sandler, Alan I. (author), Interactions of Oral Coumarin Anticoagulants with Other Drugs, 146

Secobarbital, interactions, 146

Self-medication, physician, 227

Severson, Richard W. (co-author), Prediction of Pharmacological Stability of Parenteral Solutions II., 243

Silicone oil, comparison with hydrocortisone in arthritis, 111

Sinequan, see Doxepin

Sister Jane M. Durgin, (co-author), A Clinical Study of Drug Interaction and Anticoagulant Therapy, 300

Skeletal muscle relaxants, interactions, 217

SKF 525-A, see Proadifen

Skin bank fluid, sterile, formulation, 97

Smallpox vaccine, in herpetic ulcers, 225

Smallpox vaccination, childhood, 53

Smith, William E. (author), Using the Patient Drug Profile, 73

Sodium aminosaliclate solution, stability, 16

Sodium bicarbonate injection, 216

Sodium cyclamate, carcinoma study in mice, 166, 226

Sodium fluoride, in osteoporosis, 198

Sodium metabisulfite, epinephrine stabilizer, 15

Sodium nitrite, in cold sterilization, 149

Sodium nitroprusside, 187

Solvents, for formulations, 16

Space cabin environments, effects of drugs, 291

Sperm diluting fluid, formulation, 97

Spironolactone
excretion data, 190
interaction, 167

Stability
effect of light and oxygen, 15
testing, 44

Standards, drug, 257

Statistics, new drugs, 116

Sterility, testing, 249

Sterilization
ethylene oxide, 313
gamma radiation, 314
gas, 282
manufacturing facility, 282
plastic bins and bags, 279
testing, 100
x-ray, 282

Steroids
adverse reactions, 353
metabolism of hormones, 351
new derivatives, 294

Streptomycin, synergism with vancomycin, 225

SU-13437, new hypolipidemic, 53

Succinylcholine, interactions, 217

Sulfadiazine, adverse reaction, 221

Sulfamethazine, excretion data, 190

Sulfamethoxazole, and trimethoprim, in systemic nocardiosis, 352

Sulfamethoxypyrazine, dosage regimen calculation, 164

Sulfamylon cream, see Mafenide cream

Sulfisoxazole, interactions, 146

Sulfobromophthalein (BSP), effect of halothane on clearance, 261

Sulfomethoxine, toxicity, 227

Superstine, Edward (co-author)
Ampicillin and Carbenicillin Stability, 204
Fluorouracil Treatment of Multicentric Basal Cell Carcinoma and Actinic Hyperkeratosis, 181

Suxamethonium, interactions, 217

Systemic nocardiosis, new treatment, 352

T

Tablets
disintegration test, 92
dissolution rate, 132
psychological effects of colors, 260

Talwin, see Pentazocine

Tandearil, see Pyrazole compounds

Temazepam, in insomnia, 68

Teratogenicity, 149

Teslac, see Testolactone

Testolactone (Teslac - Squibb), 116

Tetracosactrin, depot, 67

Tetracycline
azotemia reaction, 68, 166
excretion data, 190
interactions, 146
in renal failure, 353

Tetracycline and Chloromycetin combination (Lederle - England), 116

Therapeutic equivalence, 116, 257

Therapeutic incompatibilities, 240

Thioridazine, adverse reaction, 221

Thomas, Terry (co-author), Treatment of Hypertensive Emergencies with Sodium Nitroprusside, 187

Thrombin, interactions, 251

Thyrocalcitonin, metabolism, 351

d-Thyroxine, interactions, 146

Tilorone, antiviral activity, 352

Tolbutamide
excretion data, 190, 232
half-life, 291
interactions, 146
potentiation of action, 294

Toluidine blue, in diagnosis of cancer, 260

Toussignaut, D. R. (author), IPA in the 70's (edit.), 87

Toxicity studies, cosmetics, 49

Toxicology, 49

Tracheal instillation in animals, 293

Triacetoxanthracene, in psoriasis, 292

2,4,5-Trichlorophenoxyacetic acid, teratogenicity, 295

Trifluoperazine, adverse reaction, 221

Trihexyphenidyl, interactions, 88

Trimethoprim, and sulfamethoxazole, in systemic nocardiosis, 352

Tyramine, drug interactions, 174

U

Ulcerogenics, 307

Ultrafiltration, 280

Ultrapure water, manual on, 15

Ultrasonic cleaning, 44

United States Pharmacopeia
standards, 257
sterility tests, 214

United States Pharmacopeia, editorial, 3

United States Pharmacopeial Convention, resolutions, 168

University of Cincinnati, residencies, 168

Urate binding, effect of drugs, 138

Urinary excretion
data, 190, 232
effect of variation on biological half-life, 332

U.S. Food and Drug Administration, new drugs, 1969, 116

V

Vancomycin, synergism with streptomycin, 225

Venous thrombosis, prevention, 185

Virginiamycin, bacteriological evaluation, 164

Vitamin B complex, stability, 156

W

Wagner, John G. (author), Biopharmaceutics, 17, 32, 77, 92, 132, 160, 190, 232

Ward, Charles O. (author), Toxicologic Evaluation of Cosmetics, 49

Ward, Charles O. (co-author), A Clinical Study of Drug Interaction and Anticoagulant Therapy, 300

Warfarin
interactions, 10, 167, 294, 300
metabolism, 348

World Health Organization, International Drug Monitoring, the Role of the Hospital, 101

Wuest, J. Richard (author)
Development of Policies and Procedures in an I.V. Additive Program, 183, 213, 279
Justifying an I.V. Additive Program, 125
Staffing an I.V. Additive Program, 153

X-Y-Z

Zinc, elemental, poisoning from ingestion, 261

NOW AVAILABLE . . .

Bound Copies of DRUG INTELLIGENCE AND CLINICAL PHARMACY

Volume	Year	Price
1	1967	\$12.00
2	1968	\$12.00
3	1969	\$12.00
4	1970	\$14.00

available February 1971

The above prices apply if your check accompanies the order; if the books are to be billed, add \$1.00 to price to cover handling charges. Students will be granted a special discount of 20 percent.

INDEX TO ADVERTISERS

Abbott Laboratories
I.V. Additive Service, F-IFC, Ap-IFC, Ma-IBC, Je-IBC, 172, Ag-IBC, S-IBC, O-IFC, N-IFC, D-IFC

Handbooks of Clinical Pharmacy
1. Handbook of Drug Interactions, 182, 202, 263, 270, N-IBC, D-IBC

Hoechst Pharmaceutical Company, Division of American Hoechst Corp.
Institutional, Ma-IBC
Unit dose packaging, JI-IFC

Eli Lilly and Company
Ident-Dose, Ja-IFC, Mr-IBC, opposite 127, JI-IBC, 230, 298
Keflin ampoule, F-IBC, Ap-IBC, Je-IBC, Ag-IFC, O-IBC, 330

J. B. Lippincott Company
New pharmacy and pharmacology texts, opposite 126

Marion Laboratories, Inc.
Sign of Perfection, institutional, JI-IBC, Ag-IBC, S-IBC, O-IBC, N-IBC

Mead Johnson and Company
1970 Grants, 171

Paul de Haen, Inc.
Drug information systems, 167, 200, 277, 310

Rachelle Laboratories, Inc.
Tetracycline, chloramphenicol, 165

A. H. Robins Company, Inc.
Mystery Man, institutional, Je-IFC, D-IBC
Today's hospital nurse commands a new station, Ma-IFC, 269

Roche Laboratories, Division of Hoffmann-LaRoche, Inc.
Announces expiration dates on all products, S-IFC
Hospital Pharmacy Research Grant Program, Ma-center spread, 142-143
Roche Hospital Pharmacy Information Service, 28 and Ja-IBC, 56 and Fe-IBC, 84 and Mr-IBC
Tel-E-Dose, 266-267

Stuart Pharmaceuticals, Division of Atlas Chemical Industries
Mylanta unit dose, 2, 58, 86, 114, 144

University of Cincinnati
Applied Biopharmaceutics, continuing education course, 170, 268

